Varun Saxena, Lisa Nyberg, Marypat Pauly, Aditi Dasgupta, Anders Nyberg, Barbara Piasecki, Bradley Winston, Jacquelyn Redd, Joanna Ready, Norah A. Terrault – 1 June 2015 – Risks and benefits of simeprevir plus sofosbuvir (SIM+SOF) in patients with advanced cirrhosis are unknown. We assessed the safety and sustained virological responses (SVR) of SIM+SOF with and without ribavirin (RBV) in patients with Child‐Pugh (CP)‐B/C versus CP‐A cirrhosis and compared to matched untreated controls.

Binxia Chang, Ming‐Jiang Xu, Zhou Zhou, Yan Cai, Man Li, Wei Wang, Dechun Feng, Adeline Bertola, Hua Wang, George Kunos, Bin Gao – 29 May 2015 – Obesity and alcohol consumption often coexist and work synergistically to promote steatohepatitis; however, the underlying mechanisms remain obscure. Here, we demonstrate that feeding mice a high‐fat diet (HFD) for as little as 3 days markedly exacerbated acute ethanol binge–induced liver neutrophil infiltration and injury. Feeding mice with an HFD for 3 months plus a single binge of ethanol induced much more severe steatohepatitis.

Ângelo Zambam de Mattos, Angelo Alves de Mattos – 29 May 2015

Binxia Chang, Ming‐Jiang Xu, Zhou Zhou, Yan Cai, Man Li, Wei Wang, Dechun Feng, Adeline Bertola, Hua Wang, George Kunos, Bin Gao – 29 May 2015 – Obesity and alcohol consumption often coexist and work synergistically to promote steatohepatitis; however, the underlying mechanisms remain obscure. Here, we demonstrate that feeding mice a high‐fat diet (HFD) for as little as 3 days markedly exacerbated acute ethanol binge–induced liver neutrophil infiltration and injury. Feeding mice with an HFD for 3 months plus a single binge of ethanol induced much more severe steatohepatitis.

Travis B. Dick, Lance S. Lindberg, Debra D. Ramirez, Michael R. Charlton – 29 May 2015 – The US Food and Drug Administration has recently approved a number of new direct‐acting antiviral agents for the treatment of chronic hepatitis C virus that have significantly increased the likelihood of a virological cure. These agents are highly effective but present a substantial risk for a host of clinically relevant drug‐drug interactions. These interactions must be considered both when starting and stopping any medication, including over‐the‐counter medications and herbal supplements.

Kheng Choon Lim, Pierce K.H. Chow – 29 May 2015

Travis B. Dick, Lance S. Lindberg, Debra D. Ramirez, Michael R. Charlton – 29 May 2015 – The US Food and Drug Administration has recently approved a number of new direct‐acting antiviral agents for the treatment of chronic hepatitis C virus that have significantly increased the likelihood of a virological cure. These agents are highly effective but present a substantial risk for a host of clinically relevant drug‐drug interactions. These interactions must be considered both when starting and stopping any medication, including over‐the‐counter medications and herbal supplements.

David E. Kleiner – 27 May 2015 – Watch a video presentation of this article

David E. Kleiner – 27 May 2015 – Watch a video presentation of this article

Amy G. Feldman, Ronald J. Sokol, – 27 May 2015 – Watch a video presentation of this article